Clinical Trials Logo

Type 2 Diabetes Mellitus clinical trials

View clinical trials related to Type 2 Diabetes Mellitus.

Filter by:

NCT ID: NCT05348122 Not yet recruiting - Clinical trials for Type 2 Diabetes Mellitus

A Study of TG103 Injection in Type 2 Diabetes Subjects

Start date: June 15, 2022
Phase: Phase 2
Study type: Interventional

The primary objective of this trial is to evaluate the efficacy of different doses and frequencies of administration of TG103 injection in the treatment of type 2 diabetes.

NCT ID: NCT05331339 Completed - Clinical trials for Type 2 Diabetes Mellitus

Real-life Efficacy of Insulia® Tool in Patients Living With Type 2 Diabetes Treated With Basal Insulin Therapy as Part of a National Telemedicine Program (ETAPES)

INSULIA
Start date: November 2, 2022
Phase:
Study type: Observational

The purpose of this study was to evaluate the INSULIA digital tool (automation of basal insulin dose calculation in type 2 diabetes) within the framework of a French national telemedicine experimentation program (ETAPES) in a single-center study. The assumption is that a better metabolic control with this tool.

NCT ID: NCT05326490 Not yet recruiting - Clinical trials for Type 2 Diabetes Mellitus

Study to Evaluate the Efficacy and Safety of PB-201 in Type 2 Diabetic Mellitus Patients With Poor Glycemic Control Via Metformin Hydrochloride Monotherapy

Start date: May 30, 2022
Phase: Phase 3
Study type: Interventional

This is a Multi-center, Randomized, Double-Blinded, Parallel and Placebo-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of PB-201 in Type 2 Diabetic Mellitus Patients with Poor Glycemic Control via Metformin Hydrochloride Monotherapy

NCT ID: NCT05313529 Recruiting - Clinical trials for Type 2 Diabetes Mellitus

Effects of Liraglutide, Empagliflozin and Linagliptin on the Cognitive Function in T2DM Patients With Mild Cognitive Impairment: a Multicenter, Randomized, Parallel Controlled Clinical Trial

LIGHT-MCI
Start date: October 8, 2022
Phase: N/A
Study type: Interventional

This is a prospective, randomized, open label, parallel, 76-week study to explore and evaluate the therapeutic effects of Liraglutide, Empagliflozin and Linagliptin on the cognitive function, olfactory function, and odor-induced brain activation in T2DM patients with mild cognitive impairment (MCI).

NCT ID: NCT05297045 Terminated - Clinical trials for Type 2 Diabetes Mellitus

A Study of Oral GLP1RA RGT001-075 in Adults With Type 2 Diabetes

Start date: March 29, 2022
Phase: Phase 2
Study type: Interventional

This is a phase 2 study designed to evaluate the efficacy of daily (QD) oral RGT001-075 GLP1 receptor agonist relative to placebo after up to 16 weeks of double-blind treatment as determined by mean change from baseline in HbA1c in adult patients with Type 2 Diabetes Mellitus (T2DM) who have inadequate glycemic control with diet and exercise and stable metformin treatment.

NCT ID: NCT05296044 Recruiting - Clinical trials for Type 2 Diabetes Mellitus

To Evaluate the Efficacy and Safety of JT-003 add-on in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin

Start date: April 5, 2022
Phase: Phase 3
Study type: Interventional

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of JT-003 Add-on in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Metformin and Dapagliflozin

NCT ID: NCT05295160 Completed - Obesity Clinical Trials

Fasting-Associated Immune-metabolic Remission of Diabetes

FAIR
Start date: September 25, 2020
Phase: N/A
Study type: Interventional

People with a body mass index above 28 kg/m² and an onset of type 2 diabetes within the last 4 years had a remission (HbA1c <6.5% without medication) of diabetes in over 80% upon weight loss of 15 kg. Longer duration of diabetes reduced the chance of remission. The investigators will test whether there is a difference in remission upon weight loss of 15 kg using formula low calorie diets between subjects with a diabetes duration of <4 years vs. >8 years and oral treatment as primary end points. The immune metabolic programming of circulating monocytes will be investigated in detail regarding trained innate immunity and the endocrine responses will be determined using meal challenge tests.

NCT ID: NCT05287906 Enrolling by invitation - Clinical trials for Type 2 Diabetes Mellitus

A Trial to Assess Steviol Glycosides on Acute Appetite Hormone Release

Start date: April 15, 2022
Phase: N/A
Study type: Interventional

The objectives of this trial are to assess the effects of steviol glycoside alone or in combination with a glycemic carbohydrate on blood glucose and endocrine and gut hormone secretion vs. water and glucose in individuals with normal weight, overweight and type 2 diabetes mellitus (T2DM).

NCT ID: NCT05286853 Not yet recruiting - Clinical trials for Type 2 Diabetes Mellitus

A Study of Renal Autologous Cell Therapy (REACT) in Participants With Type 2 Diabetes and Chronic Kidney Disease

Start date: July 2024
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the safety and efficacy (including durability) of up to 2 REACT injections given 3 months (+30 days) apart and delivered percutaneously into biopsied and non-biopsied contralateral kidneys in participants with T2DM and CKD.

NCT ID: NCT05281029 Recruiting - Clinical trials for Type 2 Diabetes Mellitus

Observational Study Gemigliptin in Patients Aged ≥ 65 Years With Type 2 Diabetes Mellitus

Start date: June 24, 2021
Phase:
Study type: Observational

The aim of this study is to evaluate safety and effectiveness of treatment with gemigliptin for 24 weeks in Korean patients aged ≥ 65 years with type 2 diabetes mellitus in routine clinical settings